Synthflow AI Raises $20M to Transform the $168B Global Conversational AI Market With Enterprise AI Voice Agents
BERLIN--(BUSINESS WIRE)-- Synthflow AI, the voice AI platform for automated phone calls, today announced a $20M Series A investment round to drive the next wave of enterprise adoption for AI voice agents. The round is led by Accel, with participation from existing investors Atlantic Labs and Singular. This follows the company's seed round last year, bringing the total funding to $30M. The new capital will support global expansion, including the opening of a new office in the US, and accelerate development of its best-in-class voice AI agent platform.
After decades of slow progress, voice AI technology is at a turning point. Recent breakthroughs have made it viable for enterprises to deploy AI voice agents at scale across a wide range of use cases. From customer service to appointment scheduling and lead qualification, these agents can transform global operations, delivering exceptional support at a fraction of the cost.
For contact centers and business process outsourcing (BPO) companies that dominate the $159B US customer service market, this shift presents a major growth opportunity, driven by always-on voice agents that deliver natural conversations. Until now, deploying this technology while standing out in an increasingly crowded space has been a challenge, demanding deep AI expertise, specialized teams, inflated budgets, and drawn-out onboarding.
Founded in 2023 by serial entrepreneurs Albert Astabatsyan, Hakob Astabatsyan, and Sassun Mirzakhan-Saky, Synthflow AI democratizes access to advanced voice AI with a no-code platform that lets enterprises easily create, deploy and scale natural-sounding, cost-effective voice agents tailored to their business needs.
Designed for non-technical users, Synthflow AI's white-label voice agents require zero code, are highly customizable, and can handle everything from simple inquiries to complex workflows including customer support, appointment scheduling, inbound lead qualification, AI-to-human call transfers, and collecting and sharing real-time information at scale. With over 200 integrations across calendars, CRMs and telephony systems, Synthflow AI can be implemented rapidly and cost effectively, a contrast to the typical six-month onboarding required by legacy vendors.
Synthflow AI's pioneering AI Voice Operating System (OS) is built to be indistinguishable from a human voice, offering the best-in-class quality, low latency, and high reliability. It can handle complex, high-value use cases with no human intervention. Since its seed round in 2024, Synthflow AI has expanded its R&D team to further boost product performance and has rapidly scaled to integrate with BPO providers and contact centers worldwide.
Synthflow AI agents have already delivered measurable impact:
Over 5 million hours of contact center operations saved
35% more calls answered compared to non-AI operators
45 million calls handled with a 99.9% uptime
Hakob Astabatsyan, co-founder and CEO of Synthflow AI, said: 'Businesses and their customers are becoming increasingly comfortable communicating with AI agents. Our mission at Synthflow AI is to make high-quality, low-cost AI voice agents more accessible to improve customer services everywhere. The BPO and contact center market represents a massive opportunity for us, and we're already experiencing significant growth in this sector thanks to the simplicity of our no-code platform and the reliability and quality of our AI voice agents. This funding will help us accelerate this growth and scale our product so that we can continue pioneering Voice AI technology globally.'
Luca Bocchio, Partner at Accel, said: 'Voice AI is at a real inflection point, voice agents have been improving rapidly and have never been more cost effective to deploy. The Synthflow AI team is seizing the moment from legacy players by making this technology more accessible. The market opportunity for deploying voice agents in traditional customer support use cases is vast and, as infrastructure continues to evolve and AI capabilities improve further, new emerging use cases in areas such as healthcare, financial services, education and more will continue to open up. Hakob and the team's technical expertise and momentum so far have been impressive. We're delighted to be investing in their vision and joining the journey ahead.'
For more information about Synthflow AI, visit synthflow.ai
About Synthflow AI
Synthflow AI is a no-code platform for deploying voice AI agents that automate phone calls across contact center operations and business process outsourcing (BPO) at scale. A G2 Grid Leader for AI Agents, Synthflow helps mid-market and enterprise companies manage routine calls to save teams time and resources without increasing headcount. Backed by Accel and trusted by over 1,000 customers, its growth reflects a broader industry shift toward sophisticated and accessible conversational AI in a global market projected to reach $168.2 billion.
About Accel
Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Bumble, Celonis, CrowdStrike, Deliveroo, Fiverr, Freshworks, Miro, Qualtrics, Scale, Segment, Slack, Spotify, Supercell, and UiPath are among the companies Accel has backed over the past 40+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
9 minutes ago
- Business Wire
PennyMac Mortgage Investment Trust Declares Second Quarter 2025 Dividend for Its Common Shares
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--PennyMac Mortgage Investment Trust (NYSE: PMT) announced today that its Board of Trustees declared a cash dividend of $0.40 per common share of beneficial interest for the second quarter of 2025. This dividend will be paid on July 25, 2025, to common shareholders of record as of July 11, 2025. About PennyMac Mortgage Investment Trust PennyMac Mortgage Investment Trust is a mortgage real estate investment trust (REIT) that invests primarily in residential mortgage loans and mortgage-related assets. PMT is externally managed by PNMAC Capital Management, LLC, a wholly-owned subsidiary of PennyMac Financial Services, Inc. (NYSE: PFSI). Additional information about PennyMac Mortgage Investment Trust is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, regarding management's beliefs, estimates, projections and assumptions with respect to, among other things, the Company's financial results, future operations, business plans and investment strategies, as well as industry and market conditions, all of which are subject to change. Words like 'believe,' 'expect,' 'anticipate,' 'promise,' 'plan,' and other expressions or words of similar meanings, as well as future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' or 'may' are generally intended to identify forward-looking statements. Actual results and operations for any future period may vary materially from those projected herein and from past results discussed herein. Factors which could cause actual results to differ materially from historical results or those anticipated include, but are not limited to: changes in interest rates; the Company's ability to comply with various federal, state and local laws and regulations that govern its business; volatility in the Company's industry, the debt or equity markets, the general economy or the real estate finance and real estate markets; events or circumstances which undermine confidence in the financial and housing markets or otherwise have a broad impact on financial and housing markets; changes in real estate values, housing prices and housing sales; changes in macroeconomic, consumer and real estate market conditions; the degree and nature of the Company's competition; the availability of, and level of competition for, attractive risk-adjusted investment opportunities in mortgage loans and mortgage-related assets that satisfy the Company's investment objectives; the inherent difficulty in winning bids to acquire mortgage loans, and the Company's success in doing so; the concentration of credit risks to which the Company is exposed; the Company's dependence on and potential conflicts with its manager, servicer and their affiliates; the Company's ability to mitigate cybersecurity risks, cybersecurity incidents and technology disruptions; the development of artificial intelligence; the availability, terms and deployment of short term and long term capital; the adequacy of the Company's cash reserves and working capital; the Company's ability to maintain the desired relationship between its financing and the interest rates and maturities of its assets; the timing and amount of cash flows, if any, from the Company's investments; the Company's substantial amount of indebtedness; the performance, financial condition and liquidity of borrowers; the Company's exposure to risks of loss and disruptions in operations resulting from severe weather events, man-made or other natural conditions, including climate change and pandemics; the ability of the Company's servicer, which also provides the Company with fulfillment services, to approve and monitor correspondent sellers and underwrite loans to investor standards; incomplete or inaccurate information or documentation provided by customers or counterparties, or adverse changes in the financial condition of the Company's customers and counterparties; the Company's indemnification and repurchase obligations in connection with mortgage loans it purchases, sells or securitizes; the quality and enforceability of the collateral documentation evidencing the Company's ownership and rights in the assets in which it invests; increased rates of delinquency, defaults and forbearances and/or decreased recovery rates on the Company's investments; the performance of mortgage loans underlying mortgage-backed securities in which the Company retains credit risk; the Company's ability to foreclose on its investments in a timely manner or at all; increased prepayments of the mortgages and other loans underlying the Company's mortgage-backed securities or relating to the Company's mortgage servicing rights and other investments; risks associated with the discontinuation of LIBOR; the degree to which the Company's hedging strategies may or may not protect it from interest rate volatility; the effect of the accuracy of or changes in the estimates the Company makes about uncertainties, contingencies and asset and liability valuations when measuring and reporting upon the Company's financial condition and results of operations; the Company's ability to maintain appropriate internal control over financial reporting; the Company's ability to detect misconduct and fraud; developments in the secondary markets for the Company's mortgage loan products; legislative and regulatory changes that impact the mortgage loan industry or housing market; regulatory or other changes that impact government agencies or government-sponsored entities, or such changes that increase the cost of doing business with such agencies or entities; federal and state mortgage regulations and enforcement; changes in government support of homeownership; changes in government or government-sponsored home affordability programs; changes in the Company's investment objectives or investment or operational strategies, including any new lines of business or new products and services that may subject it to additional risks; limitations imposed on the Company's business and its ability to satisfy complex rules for it to qualify as a REIT for U.S. federal income tax purposes and qualify for an exclusion from the Investment Company Act of 1940 and the ability of the Company's subsidiaries to qualify as REITs for U.S. federal income tax purposes; changes in governmental regulations, accounting treatment, tax rates and similar matters; the Company's ability to make distributions to its shareholders in the future; the Company's failure to deal appropriately with issues that may give rise to reputational risk; and the Company's organizational structure and certain requirements in its charter documents. You should not place undue reliance on any forward-looking statement and should consider all of the uncertainties and risks described above, as well as those more fully discussed in reports and other documents filed by the Company with the Securities and Exchange Commission from time to time. The Company undertakes no obligation to publicly update or revise any forward-looking statements or any other information contained herein, and the statements made in this press release are current as of the date of this release only.
Business Wire
9 minutes ago
- Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy. Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP) Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD) Q4 2025 - First in human study of ACP-271 in healthy volunteers Q1 2026 - Potential approval from European Medicines Agency for trofinetide Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer's disease psychosis (ADP) 2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET) 'Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,' said Catherine Owen Adams, Chief Executive Officer. 'As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.' 'At Acadia, we're building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,' said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. 'Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.' The Company will be discussing the following pipeline programs today: ACP-101 (intranasal carbetocin) A long-acting analogue of human oxytocin for the potential treatment of PWS ACP-204 A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP ACP-211 An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD ACP-711 A selective GABA A -α3 modulator targeting the potential treatment of ET ACP-271 A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington's Disease To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue,' 'opportunity,' 'goal' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and product candidates; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including estimates of potential commercial product and pipeline peak sales and potential net sales of our commercial franchises in 2025, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks inherent with product candidate development, including risks of unsuccessful clinical trial enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
Business Wire
10 minutes ago
- Business Wire
AXL and Dentons Announce Strategic Partnership to Advance Legal Innovation with AI
TORONTO--(BUSINESS WIRE)--Today, AXL, a Canadian venture studio transforming AI research into high-growth companies, and Dentons, Canada's Global Law Firm, have announced a strategic partnership to shape the legal industry's next evolution with AI. Together, Dentons and AXL will co-develop ventures that will accelerate the pace of innovation across the legal field and bring outdated workflows, pricing, access, and indeed, the very definition of legal services, into the future. Dentons also becomes the exclusive legal partner to AXL and the preferred provider to its growing portfolio of ventures, bringing legal insight into the early stages of AI innovation and commercialization. 'This partnership reflects our ongoing commitment to staying at the forefront of legal innovation and AI,' said Tim Haney, CEO of Dentons Canada. 'By collaborating closely with AXL, we will unlock new models for how technology can enable us to provide exponential value to our clients through innovation.' AXL is led by one of Canada's top innovators, Dr. Daniel Wigdor, who is fuelling Canada's AI research-to-commercialization pipeline with a mission to launch 50 AI-powered companies over the next five years. Its proprietary model merges cutting-edge AI research from the University of Toronto with real-world industry insight through its AI Catalyst program, a corporate partnership initiative designed to validate and accelerate breakthrough ideas. 'We're proud to partner with Dentons, a firm with global scale, legal sophistication, and a strategic AI roadmap that's moving legal innovation forward,' said Dr. Daniel Wigdor, Co-Founder and CEO of AXL. 'Together, we're launching companies that will define what practical and scalable AI applications will look like in practice.' Dentons joins a growing group of leading Canadian organizations collaborating with AXL in 'think tanks' to explore high-impact applications of AI that will drive efficiency in their industries. Beyond shaping the direction of new ventures, Dentons will be involved in bringing companies to market, ensuring each company is built on genuine market demand, atop deep customer insights, and is positioned for scale. 'With AXL, we are not just offering legal services to startups – we are contributing to the formation of AI ventures from day one,' said Mike Hollinger, Partner and Toronto Leader of Dentons' Venture Technology and Emerging Growth Companies Group. 'Together, we are reimagining how legal services are delivered. This partnership puts Dentons and AXL at the center of that transformation.' Through collaboration and visionary thinking, Dentons and AXL will co-create and deliver cutting-edge AI tools to drive innovation – from Canada, for the world. 'The last time legal services fundamentally changed, it was because of a research lab,' added Dr. Wigdor. 'Lawyers modelled the modern law firm after Thomas Edison's lab — teams of associates supporting partners to boost output and value. Dentons and AXL are now picking up where that transformation left off, building the next wave of practical, scalable AI applications for law.' To learn more about this strategic partnership, watch this video with Tim Haney and Daniel Wigdor at Dentons' North American AI Legal Summit. Daniel's keynote address can also be viewed here. To learn more about how AXL is fuelling Canada's AI research-to-commercialization pipeline, visit their website at About Dentons Dentons is Canada's Global Law Firm – capitalizing on expansive geographic reach and national strength to provide a tailored experience for clients, wherever they do business. We collaborate with our clients and incorporate our deep understanding of their priorities to achieve the best outcome, blending the creative with the practical. We are more than legal advisors, we are global problem-solvers. Globally ranked in the Top 10 for venture and M&A deals (Pitchbook), Dentons' Venture Technology and Emerging Growth Companies Group has acquired a reputation as one of Canada's top legal advisors to growth-oriented technology companies. Access our Startup Resource Hub for legal insights and templates. Redefining possibilities. Together, everywhere. For more information, visit About AXL AXL is a Canadian venture studio transforming world-class research into high-growth companies that shape the future of applied AI. Led by seasoned tech entrepreneurs and applied AI experts, AXL's mission is to ensure Canada's top breakthroughs are built and scaled at home. By connecting academia with real market demand and full-stack venture creation, AXL helps Canada move from invention to impact, anchoring talent, intellectual property, and long-term economic value within the country.
